Project Grant R01HL179196
Award Date
8/1/25
Completion Date
6/30/30
Dollars Obligated
$770K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Stanford, CA 94305, USA
Similar Awards
This $834,249 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a comparative study of clinical outcomes, patient experiences, and mechanistic insights between transcatheter and surgical treatment of degenerative mitral regurgitation (DMR). The study aims to provide long-term data on clinical effectiveness, safety, and patient-reported outcomes to inform treatment selection and guide patient care. It will also utilize...
This $705,405 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to investigate the role of adventitial fibroblasts, an understudied cell population, in the development and progression of atherosclerosis. The key objectives are to: Determine the mechanism by which targeted genetic ablation of adventitial fibroblasts decreases atherosclerotic plaque formation, despite these cells not directly contributing to the intimal...
This federal Project Grant award, valued at $181,392.00 and provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research to optimize surgical procedures for congenital aortic valve disease. The Principal Investigator, Dr. Alexander D. Kaiser, will leverage a novel computational modeling framework to (1) simulate and optimize the leaflet geometry of bicuspidization repair and bioprinted valve replacement procedures, (2) validate the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $392,037 to New York University School of Medicine to conduct research on improving cardiovascular outcomes for patients undergoing non-cardiac surgery. The key objectives of the project are to: 1) survey potential study sites to assess their capacity for patient enrollment and management of patients with myocardial injury after non-cardiac surgery (MINS);...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,406,736 to the Palo Alto Veterans Institute for Research (PAVIR) to conduct research aimed at understanding the mechanisms and impact of coronary artery patterning. The overarching goal is to identify pathways that could stimulate coronary artery growth and collateralization, with the potential to develop new therapies to improve outcomes for individuals with...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is focused on leveraging deep learning to link normal variation in aortic valve hemodynamics to the pathogenesis of aortic stenosis. The $722,299 award to The Regents of the University of California, San Francisco (UCSF), with a period of performance from August 1, 2025 to July 31, 2030, will enable UCSF to measure aortic valve...
This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $259,464 to The Leland Stanford Junior University to conduct research on "Mitochondrial Therapy in Conjunction with Guideline Directed Medical Therapy in Cardiomyopathy". The primary objectives are to: 1) Determine the mechanism of the protective effects of mitochondria-rich extracellular vesicles (M-EVs) in combination with guideline-directed...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $256,776 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Irvine (UCI). The objective of this 2-year grant, awarded on August 20, 2024, is to develop novel "metasurface optical guidewires" for therapeutic applications to treat highly stenotic coronary artery calcification (CAC) lesions, which pose significant challenges to successful percutaneous coronary...
This Project Grant award of $1,102,957 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to The Leland Stanford Junior University will fund research to investigate the relationship between cancer and cardiovascular disease. The project aims to: 1) use epidemiological and genetic approaches to map causal links and shared genetic factors between the two disease states; 2) leverage advanced mouse models to prove that cancer can directly promote...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $331,344 to The Leland Stanford Junior University to conduct research on the gene regulatory mechanisms of the coronary artery disease gene PRDM16 and its impact on smooth muscle cell phenotypic modulation. The 5-year project, starting January 1, 2025, aims to elucidate how PRDM16, an epigenetic modifier, regulates the transition of...